International Study Group for Behçet’s disease. Criteria for diagnosis of Behçet’s disease. Lancet 335:1078–1080, 1990
Ohno E, Ohtsuka E, Watanabe K, Kohno T, Takaoka K, Saburi Y, Kikuchi H, Nasu M. Behçet’s disease associated with myelodysplastic syndromes. Cancer 79:262–268, 1997
Sakane T, Takeno M, Suzuki N, Inaba G. Behçet’s disease. N Engl J Med 341:1284–1291, 1999
Gul A. Behcet’s disease: An update on the pathogenesis. Clin Exp Rheumatol 19:S6–S12, 2001
Rotteveel FT, Kokkelink I, van Lier RA, Kuenen B, Meager A, Miedema F, Lucas CJ. Clonal analysis of functionally distinct human CD4+ T cell subsets. J Exp Med 168:1659–1673, 1988
Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51:189–199, 1982
Clark DM, Lampert IA. Apoptosis is a common histopathological finding in myelodysplasia: The correlate of ineffective hematopoiesis. Leuk Lymphoma 2:415–418, 1990
Arimura K, Arima N, Matsushita K, Ohtsubo H, Fujiwara H, Kukita T, Ozaki A, Hagiwara T, Hamada H, Yoshino K, Tei C. Matrix metalloproteinase inhibitor reduces apoptosis induction of bone marrow cells in MDS-RA. Eur J Haematol 73:17–24, 2004
Karuvannur S, Lipstein E, Brennessel D, Rosner F. Atypical Behçet’s syndrome in a patient with myelodysplastic syndrome. Mount Sinai J Med 68:403–405, 2001
Oh EJ, Yoon JS, Park YJ, Cho CS, Kim BK. Behçet’s disease associated with myelodysplastic syndrome. J Korean Med Sci 14:685–687, 1999
Behçet’s Disease Research Committee of Japan. Criteria for diagnosis of Behçet’s disease. In Annual Report of Behçet’s Disease, Y Mizushima, ed. Tokyo, Research Committee of Japan, Ministry of Health and Welfare of Japan, 1986
Imamura Y, Kurokawa MS, Yoshikawa H, Nara K, Takada E, Masuda C, Tsukikawa S, Ozaki S, Matsuda T, Suzuki N. Involvement of Th1 cells and heat shock protein 60 in the pathogenesis of intestinal Behcet’s disease. Clin Exp Immunol 139:371–378, 2005
Koarada S, Haruta Y, Tada Y, Ushiyama O, Morito F, Ohta1 A, Nagasawa K. Increased entry of CD4+ T cells into the Th1 cytokine effector pathway during T-cell division following stimulation in Behçet’s disease. Rheumatology 43:843–851, 2004
Nagafuchi H, Takeno M, Yoshikawa H, Kurokawa MS, Nara K, Takada E, Masuda C, Mizoguchi M, Suzuki N. Excessive expression of Txk, a member of the Tec family of tyrosine kinases, contributes to excessive Th1 cytokine production by T lymphocytes in patients with Behçet’s disease. Clin Exp Immunol 139:363–370, 2004
Sloand EM, Mainwaring L, Fuhrer M, Ramkissoon S, Risitano AM, Keyvanafar K, Lu J, Basu A, Barrett AJ, Young NS. Preferential suppression of trisomy 8 versus normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome. Blood 106:841–851, 2005
Niwa Y, Miyake S, Sakane T, Shingu M, Yokoyama M. Auto-oxidative damage in Behçet’s disease—endothelial cell damage following the elevated oxygen radicals generated by stimulated neutrophils. Clin Exp Immunol 49:247–255, 1982
Yano K, Eguchi K, Migita K, Takashima H, Tamura M, Izumino K, Sasagawa I, Sadamori N, Nagataki S. Behçet’s disease complicated with myelodysplastic syndrome: A report of two cases and review of the literature. Clin Rheumatol 15:91–93, 1996
Turan B, Gallati H, Erdi H, Gurler A, Michel BA, Villiger PM. Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Behçet’s disease; soluble TNFR-75 as a biological marker of disease activity. J Rheumatol 24:128–132, 1997